RT Journal Article
SR Electronic
T1 Diagnostic accuracy of Panbio™ rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.30.21250314
DO 10.1101/2021.01.30.21250314
A1 Ngo Nsoga, Marie Thérèse
A1 Kronig, Ilona
A1 Perez Rodriguez, Francisco Javier
A1 Sattonnet-Roche, Pascale
A1 Da Silva, Diogo
A1 Helbling, Javan
A1 Sacks, Jilian A.
A1 de Vos, Margaretha
A1 Boehm, Erik
A1 Gayet-Ageron, Angèle
A1 Berger, Alice
A1 Jacquerioz-Bausch, Frédérique
A1 Chappuis, François
A1 Kaiser, Laurent
A1 Schibler, Manuel
A1 Renzoni, Adriana
A1 Eckerle, Isabella
YR 2021
UL http://medrxiv.org/content/early/2021/02/01/2021.01.30.21250314.abstract
AB Background Antigen-detecting rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 offer new opportunities for testing in the context of the COVID-19 pandemic. Nasopharyngeal swabs (NPS) are the reference sample type, but oropharyngeal swabs (OPS) may be a more acceptable sample type in some patients.Methods We conducted a prospective study in a single screening center to assess the diagnostic performance of the Panbio™ COVID-19 Ag Rapid Test (Abbott) on OPS compared with reverse-transcription quantitative PCR (RT-qPCR) using NPS.Results 402 outpatients were enrolled in a COVID-19 screening center, of whom 168 (41.8%) had a positive RT-qPCR test. The oropharyngeal Ag-RDT sensitivity compared to nasopharyngeal RT-qPCR was 81% (95%CI: 74.2-86.6). Two false positives were noted out of the 234 RT-qPCR negative individuals, which resulted in a specificity of 99.1% (95%CI: 96.9-99.9) for the Ag-RDT.For cycle threshold values ≤ 26.7 (≥ 1E6 SARS-CoV-2 genomes copies/mL, a presumed cut-off for infectious virus), 96.3% sensitivity (95%CI: 90.7-99.0%) was obtained with the Ag-RDT using OPS.Interpretation Based on our findings, the diagnostic performance of the Panbio™ Covid-19 RDT with OPS samples meet the criteria required by the WHO for Ag-RDTs (sensitivity≥80% and specificity ≥97%).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Foundation of Innovative Diagnostics (FIND), by Private HUG Foundation and by Pictet Charitable Foundation. M.T. Ngo Nsoga is a beneficiary of the excellence grant from the Swiss Confederation and the grant from the humanitarian commission of the University Hospital of Geneva. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the cantonal ethics committee (Commission Cantonale d'Ethique de la Recherche, CCER, Geneva, Nr. 2020-02323). All enrolled patients provided written informed consent form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request to the corresponding authors. Due to ethical consideration, not patient-specific data can be shared.